Prospective Trial on the Pharmacokinetics of Clopidogrel in Hemodialysis Patients

Prospective Trial on the Pharmacokinetics of Clopidogrel in Hemodialysis Patients

Introduction: Hemodialysis patients (HDPs) exhibit extensive cardiovascular risk. The widely prescribed anti-platelet agent clopidogrel is metabolically activated by cytochrome enzymes, which may be impaired by uremia and chronic low-grade inflammation, typically present in HDPs. We conducted a pros...

Full description

Saved in:
Bibliographic Details
Main Authors: Juergen Grafeneder, Wisse van Os, Iris K. Minichmayr, Katarina D. Kovacevic Miljevic, Birgit Reiter, Marcus D. Säemann, Veronika Machold-Fabrizii, Amro Ahmed, Paul Spechtl, Haris Omic, Raute Sunder-Plaßmann, Bernd Jilma, Christian Schoergenhofer, Farsad Eskandary
Format: Article
Language:English
Published: Elsevier 2024-10-01
Series:Kidney International Reports
Subjects:
cardiovascular risk
clopidogrel
cytochrome P450
hemodialysis
pharmacokinetics
platelet aggregation
Online Access:http://www.sciencedirect.com/science/article/pii/S246802492401859X
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items